BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Tandem Diabetes Care and DexCom Expand Development and Commercialization Agreement to Include Recently Approved G4™ PLATINUM CGM Sensor


1/8/2013 10:11:47 AM

SAN DIEGO, Jan. 8, 2013 /PRNewswire/ -- Tandem Diabetes Care, Inc. ("Tandem") announced today that its Development and Commercialization Agreement with Dexcom, Inc., has been expanded to include Dexcom's newest continuous glucose monitoring system, the G4 PLATINUM. Dexcom announced in October that the G4 PLATINUM was approved by the U.S. Food and Drug Administration (FDA).

"Dexcom's G4 PLATINUM sensor is the most accurate and easiest to use technology available, and fits well with our product development plans," said Kim Blickenstaff, President and Chief Executive Officer of Tandem. "Integration of continuous glucose monitoring functionality is a primary focus at Tandem, and something we intend to deliver."

According to clinical trials conducted by Dexcom, the G4 PLATINUM has improved overall accuracy and ease of use compared to the company's previous Seven Plus CGM.

The Development and Commercialization Agreement between Tandem and Dexcom is non-exclusive and limited to the U.S. market.

About Dexcom, Inc.

Dexcom, Inc. (www.dexcom.com), headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a privately held company dedicated to advancing the management of diabetes through novel technologies. The Company offers a comprehensive, user-centric and integrated approach to product design, development, and customer care. Tandem Diabetes Care is based in San Diego, Calif.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslim.

Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetesCorp.

t:slim and Tandem Diabetes Care are registered trademarks of Tandem Diabetes Care, Inc.

Dexcom is a registered trademark and Dexcom G4 PLATINUM is a trademark of Dexcom, Inc.

SOURCE Tandem Diabetes Care


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->